New research suggests that drugs like Ozempic may provide more health benefits than previously thought. These medications, known as glucagon-like peptide-1 receptor agonists (GLP-1RAs), appear to lower the risk of cardiovascular disease even before significant weight loss occurs.
A study published in Life by Professor Mary Schooling, Professor Ghada Soliman, and their team explains how semaglutide (the active ingredient in Ozempic) may work in two key ways. First, it helps reduce calorie intake, and second, it activates a crucial enzyme called adenosine monophosphate-activated protein kinase (AMPK), which regulates metabolism.
AMPK plays a central role in how the body processes energy. Other widely used medications, such as metformin for diabetes and statins for heart disease, also work through this pathway. According to Dr. Schooling, “AMPK activation is essential for effectively preventing and treating type 2 diabetes, cardiovascular disease, and related conditions like liver and kidney disease.”
The researchers believe that AMPK activation is a key factor in many effective health interventions, including diet and lifestyle changes. If this theory is correct, it could explain why certain treatments work better than others in managing metabolic diseases.
This study provides a broader understanding of how these medications might help improve health beyond weight loss. It also suggests that targeting AMPK could be a useful strategy in preventing and treating chronic diseases that significantly impact public health.
If you care about weight loss, please read studies about orange that could help obesity, and a berry that can prevent cancer, diabetes and obesity.
For more health information, please see recent studies about whole grains are key to managing waist size, blood pressure, and blood sugar.
The research findings can be found in Life.
Copyright © 2025 Knowridge Science Report. All rights reserved.
